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Abstract: Iron overload has been associated to a variety of post-transplant complications, including infections, 
sinusoidal obstructive syndrome and it is conceivable that increased hepatic iron may mimic the clinical picture of GVHD 
or even may contribute to the worsening of hepatic GVHD.  
Objectives and Methods: aim of present review was to summarize the current knowledge about diagnosis and treatment 
strategies of iron overload following HSCT.  
Results: serum ferritin may be considered as surrogate marker of iron overload and is widely used as an indicator of 
body iron status; however other noninvasive diagnostic methods, namely SQUID and MRI, may provide more precise 
information on iron burden in specific organs, such as liver and heart. Since there are not physiological tools to remove 
efficiently the excess of iron, it is of particular importance to consider iron depleting therapy. Phlebotomy should be 
considered as the first line treatment of iron overload, while iron chelators, such as deferasirox, may represent an 
alternative option for patients with an inadequate hematological recovery. 
Discussion: additional prospective studies are mandatory to investigate the relationship between iron overload and the 
outcome of patients receiving an allogeneic stem cell transplantation. 
Keywords: Iron overload, Stem cell transplantation, GVHD, Iron chelators, Phlebotomy. 
INTRODUCTION 
Allogeneic hematopoietic stem cell transplantation 
(HSCT) is an established therapy for a variety of 
malignant and non-malignant marrow disorders, 
however the risk of transplant-related complications 
represents a major drawback in the allogeneic HSCT 
setting. Age, disease and disease status may be 
considered as the main determinants of outcomes of 
patients with hematological malignancies undergoing 
HSCT. In addition to these factors, comorbidities as 
defined by a highly sensitive HCT-specific scoring 
system, have been shown to be strong independent 
patient-specific predictors of HSCT outcomes among 
patients with hematological disorders. Many different 
prognostic scoring systems have been developed, 
including a consistent number of variables potentially 
influencing the outcome of transplantation: among 
these, iron overload (IO) may be considered as a risk 
factor contributing to posttransplant toxicity. In fact, iron 
overload is a well-established adverse prognostic factor 
in patients receiving allogeneic hematopoietic stem cell 
transplantation (HSCT) for thalassemia [1, 2], but more 
recently it appears to play a similar role in patients with 
other hematological disorders [3-7]. In this respect, 
there are studies indicating that iron overload may be 
considered as a risk factor contributing to post- 
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transplant liver toxicity, veno-occlusive disease (VOD), 
infection susceptibility and graft-versus-host disease 
(GVHD) and may negatively impact survival as well [8-
10]. 
The purpose of present review is to summarize the 
knowledge on the mechanism of iron toxicity, the 
diagnosis and clinical impact of iron overload, and 
treatment options in HSCT. 
IRON HOMEOSTASIS 
Iron enters the body exclusively through the diet: 
approximately 1-2 mg of iron is absorbed from the diet 
every day. Iron is absorbed primarily in the proximal 
portion of the duodenum where is transported across 
the brush border: most dietary iron is in the ferric form 
(Fe3+) and must be reduced to ferrous iron (Fe2+) that 
enters the absorptive enterocytes through the divalent 
metal transporter 1 (DMT1). Once inside the intestinal 
epithelial cell, iron may be stored in ferritin or exported 
across the basolateral membrane of the enterocyte by 
ferroportin for delivery to transferrin and entry into the 
circulation; 65% of the iron is incorporated into red 
blood cell hemoglobin, while the rest is mainly stored in 
the liver, spleen, bone marrow, muscle and reticulo- 
endothelial macrophages. An average of 1-2 mg of iron 
is lost daily from the sloughing of skin and shedding of 
intestinal epithelium (1 mg/day), and in women, through 
menstruation (1 mg/day). Hence, there is not a 
mechanism to actively excrete iron from the body. 
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Accordingly, iron homeostasis is basically regulated at 
the level of absorption by regulatory molecules such as 
hepcidin [11, 12]. Hepcidin is a 25-amino-acid peptide 
secreted by the liver considered to have a central role 
for regulation of iron metabolism: hepcidin binds to the 
iron transporter ferroportin, expressed on enterocytes 
and macrophages, which delivers iron from inside the 
cell to the circulation. In conditions of IO the hepatic 
expression of hepcidin is upregulated resulting in decr- 
eased iron absorption from the intestine and inhibition 
of release of storage iron by downregulating the expre- 
ssion of cellular iron export protein ferroportin [13, 14]. 
Hepcidin levels increase also in presence of 
inflammatory stimuli (IL-6), whereas its expression is 
decreased in iron-deficiency states [15, 16]. 
Due to the lack of an efficient iron export system, 
multiple transfusions lead to accumulation of iron: one 
blood unit contains approximately 200-250 mg of iron 
corresponding to the amount of iron we ingest with a 
normal diet over 6 months. As a result of transfusions, 
significant iron overload can occur after as few as 10-
20 transfusions [12, 17]. 
IRON TOXICITY 
The ability of iron to accept or donate an electron 
allows it to catalyze the formation of harmful reactive 
oxygen species (ROS) such as hydroxyl radicals that 
can damage cellular membranes, proteins and DNA. 
Under normal conditions, such catalysis is minimized 
by the sequestration of iron into complexes with 
transferrin. An increase in the body iron load may, 
however, saturate the available transferrin and lead to 
the presence of high levels of non-transferrin-bound 
iron (NTBI). NTBI is a very heterogeneous form of iron, 
the binding strength of which varies with the ligand. 
The component of NTBI with the weakest binding to 
plasma biomolecules is described as labile plasma iron 
(LPI), which is redox active and chelatable. As iron is 
only weakly bound to its ligand, LPI is able to permeate 
into organs and cause tissue damage [12, 17]. 
In patients with MDS, transfusion dependency 
represents the principal mechanism of IO, although 
other relevant factors such as ineffective erythropoiesis 
may play a crucial role [17, 18]. In allogeneic HSCT 
recipients, many different causes of elevated NTBI may 
be concomitantly present [17, 19]: 
• Enhanced iron absorption due to anemia and 
underlying hematological malignancy (MDS) 
• Dysregulation of intestinal iron absorption induced 
by alloreactive T cells [20]. 
• Red cell transfusions 
• Inhibition of erythropoiesis as a result of 
preparative regimen 
• Release of cellular iron as a result of tissue injury 
due to conditioning and destruction of bone marrow 
and tumor cells secondary to preparative regimen 
In addition to iron toxicity due to the presence of 
ROS, clinical and animal data indicate that the 
presence of elevated available serum iron may 
predispose patients to bacterial and fungal infections. 
[8, 21-24] In fact, it is well known that iron is a key 
nutrient for bacteria and fungi, in particular mucorales: 
Rhizopus spp can accumulate up to a 40-fold greater 
amount of iron than can do Aspergillus fumigatus and 
Candida albicans [25-27]. 
Ferritin may also exert immunosuppressive effects 
on both T and B cells [28]. 
ASSESSMENT OF IRON OVERLOAD 
Estimation of iron burden is primarily based on 
ferritin as a surrogate for IO [29], however many 
confounding factors particularly in HSCT recipients 
may result in potential IO overestimation. In fact, 
inflammation, infections, liver damage and GVHD may 
lead to elevated serum ferritin levels [5, 29, 30]. 
Since 90% of excess iron is deposited in the liver, 
liver biopsy with estimation of LIC (liver iron concentra- 
tion) may provide and accurate measure of whole-body 
iron levels. Indeed liver biopsy with estimation of LIC is 
the validated reference method for evaluation of body 
iron stores, particularly in allogeneic HSCT recipients 
where alternative causes of hepatic dysfunction such 
as GVHD and infections should be excluded. Neverth- 
eless, hematologic patients either during the pre-
transplant period and after the transplant may be seve- 
rely thrombocytopenic and at a high risk of bleeding 
during the procedure. Accordingly, noninvasive proce- 
dures for iron overload estimation may be considered 
as preferred tools in HSCT setting [17, 31, 32]. 
Superconducting quantum interference device 
(SQUID) has been used to quantify LIC after HSCT. 
The study of Busca et al. showed that approximately 
two thirds of the patients with hyperferritinemia had 
moderate to severe iron overload as estimated by 
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SQUID. Unfortunately, the very limited availability and 
the complexity of this methodology are an obstacle to 
the widespread clinical use of SQUID [33-35]. 
Quantitative MRI techniques, including T2 and R2 
MRI have been shown to be a reliable method for 
noninvasive evaluation of LIC in both liver and heart 
(36), but more recently MRI imaging has also been 
adopted to define the impact of IO on outcomes 
following HSCT, because it can better reflect iron 
burden than does ferritin [37-39]. 
IMPACT OF IRON OVERLOAD ON SURVIVAL AND 
COMPLICATIONS AFTER HSCT 
Estimation of IO in the allogeneic HSCT setting 
gained interest in recent years. Approximately 30% to 
60% of allogeneic HSCT recipients may present a 
condition of IO either at the time of transplant or in the 
post-transplant period [35, 39, 40]. Indeed, several 
studies have investigated whether IO might have an 
impact on overall survival (OS) and transplant-related 
complications, namely bacterial and fungal infections, 
GVHD and hepatic dysfunction. 
Survival and Non-Relapse Mortality 
The harmful effect of IO on HSCT outcome was first 
demonstrated in patients with thalassemia. Lucarelli et 
al identified hepatomegaly, portal fibrosis, and the 
inadequacy of iron chelation therapy as independent 
risk factors for the outcome of thalassemic patients 
receiving HSCT [2]. According to these variables, 
patients were categorized in 3 prognostic classes 
associated to a different outcome: the 3 years 
probability of survival were 94%, 80% and 61% for 
class 1, class 2 and class 3, respectively [1]. 
The first evidence that IO may affect the outcome of 
patients with hematological malignancies has been 
reported by Altes et al. in 2002. The study showed in 
small cohort of patients (n=15 autologous and n=10 
allogeneic HSCT) that high levels of ferritin (3000 
ng/mL) and transferrin saturation 100% were 
associated with a reduced OS and increased 
transplant-related mortality (TRM) [4]. 
In 2007 Armand et al. published a retrospective 
study evaluating the prognostic impact of elevated 
pretransplantation serum ferritin in a large number of 
patients receiving an allogeneic HSCT [3]. The study 
including 590 adult patients who underwent 
myeloablative allogeneic HSCT, showed that elevated 
serum ferritin levels in AML and MDS patients were 
associated with reduced overall and disease-free 
survival . The 5-year OS for patients with pre-transplan- 
tation serum ferritin in the first quartile (0–231 ng/mL) 
was 54%, in the second quartile (232–930 ng/mL) 50%, 
in the third quartile (931–2034 ng/mL) 37% and in the 
fourth quartile (>2034 ng/mL) 27% (P<0.001). The 5-
year disease-free survival (DFS) rates, from lowest to 
highest quartile, were 43%, 44%, 34% and 27%, 
respectively (P<0.001). In MDS patients, the decreased 
survival was attributed to an increase in TRM 
(P=0.002). There was also a trend toward an increased 
risk of hepatic VOD in patients with high ferritin levels.  
In line with these preliminary results, studies by 
Mahindra et al. have confirmed the important prognos- 
tic value of pre-transplant serum ferritin [41-43]. In 
patients receiving autologous transplantation, elevated 
pre-transplant serum ferritin levels were shown to 
adversely impact survival, relapse-free survival and 
relapse mortality [41]. Elevated ferritin was shown to be 
an independent adverse risk factor in patients 
conditioned with myeloablative regimens for allogeneic 
transplantation [42] Interestingly, pretransplantation 
ferritin >1910 ng/mL was associated with decreased 
incidence of both acute and chronic GVHD consistent 
with an immunosuppressive effect of iron burden as 
evidenced by the capacity of iron to reduce CD8+ T-
cell counts [28] and influence innate and acquired 
immune responses [24, 27]. 
Similarly, in patients undergoing nonablative 
allogeneic transplantation, survival was also adversely 
affected by elevated ferritin [43-45]. 
One may argue that the transfusion load as 
mirrored by serum ferritin level may simply reflect the 
underlying disease stage [46].In this respect, results of 
a multicenter retrospective analysis of the influence of 
pre-HSCT serum ferritin (<1000 ng/mL [low] vs. 1000 
ng/mL [high]) and disease status at transplant in 261 
adults with AML, ALL and MDS have been reported 
[47]. Patients with high-risk disease were more likely to 
have serum ferritin 1000 ng/mL (P=0.041). 
Multivariate analysis showed that pre-HSCT serum 
ferritin and disease risk were independent significant 
prognostic factors for 5-year OS, DFS and non-relapse 
mortality rate (NRM). Patients with serum ferritin 1000 
ng/mL had worse OS at 5 years compared with serum 
ferritin <1000 ng/mL (36% vs. 54%; P=0.0001). DFS 
(49% vs. 31%; P=0.001) and NRM (29% vs. 43%; 
P=0.002) were also worse at 5 years. Patients with 
serum ferritin 1000 ng/mL had a worse outcome than 
patients with serum ferritin <1000 ng/mL in both 
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standard-risk patients (OS: 54% vs. 64%; P=0.043; 
DFS: 46% vs. 57%; P=0.031) and high-risk patients 
(OS: 16% vs. 35%; P=0.001; DFS: 15% vs. 34%; 
P=0.001).  
It has been demonstrated that in patients with MDS, 
transfusion dependency may be associated to a redu- 
ced survival after transplantation, and that the WPSS 
score, which includes transfusion as a prognostic 
variable, is able to stratify post-transplantation outcome 
in patients with MDS [48]. A large Italian retrospective 
study investigated the prognostic effect of transfusion 
history and iron overload on the post-transplantation 
outcome of 357 patients with MDS [49]. Transfusion-
dependency was independently associated with 
reduced OS and increased NRM. Among transfusion-
dependent patients receiving myeloablative allogeneic 
HSCT , pre-transplantation serum ferritin level had a 
significant effect on OS (P=0.01) and NRM (P=0.03) 
even after adjusting for transfusion burden and 
duration; as a consequence, it can be hypothesized 
that the negative effect of transfusion history on 
outcome might be determined at least in part by IO . 
Indeed, a large number of studies have confirmed 
the predictive value of pretransplant serum ferritin 
levels on the main parameters of the clinical outcome 
(Table 1). 
By contrast, other studies did not support the 
evidence that pretransplant high ferritin levels might 
have a relevant impact on clinical outcomes. 
Platzbecker et al. retrospectively analysed 172 
patients with de novo MDS, demonstrating that iron 
overload resulted in higher NRM, while karyotype and 
marrow blast count appeared to be the overriding 
factors for survival [50]. 
The potential role of IO on posttransplant 
complications has been investigated in the autologous 
HSCT setting as well. A retrospective analysis of 224 
patients who underwent HSCT assessed the clinical 
impact of pre-transplantation iron status on early 
transplant-related toxicity: 142 patients received autolo- 
gous HSCT and 82 allogeneic HSCT for the treatment 
of AML (n=83), acute lymphoblastic leukemia (n=35), 
MDS (n=2), myeloma (n=45) and lymphoma (n=59). 
Median pre-transplant serum ferritin was 720 ng/mL 
(range 20–9255). Overall, 143 patients had serum 
ferritin levels <800 ng/mL (low serum ferritin group) and 
81 patients had serum ferritin levels 800 ng/mL (high 
serum ferritin group). Allogeneic HSCT recipients with 
low pre-transplant serum ferritin had significantly lower 
day 100 mortality than patients with high pre-transplant 
serum ferritin (p=0.003), while there was a trend toward 
a reduced TRM among autologous HSC recipients with 
low ferritin levels (p=0.006) [51]. 
Trottier et al. defined the impact of IO on transplant 
outcomes of 88 patients, using liver magnetic reson- 
ance imaging (R2-MRI) : 60 out of the 88 patients were 
defined as having IO , based on LIC > 1.8 mg/g. 
Median ferritin was 290 and 1732 in the no-iron over- 
load and IO groups respectively. Pre-transplant ferritin 
levels only moderately correlated with LIC, but more 
importantly they did not observe an association 
between pre-transplant IO defined by R2-MRI measur- 
ed LIC and OS , NRM, relapse rate, GVHD, bacterial, 
viral or fungal infections. [52] Similar results have been 
reported by Armand et al. in a cohort of 45 patients with 
acute leukaemia and MDS who received an allogeneic 
HSCT: although serum ferritin appeared to have 
prognostic significance, pre-HSCT IO assessed by LIC 
> 5 mg/gdw was not associated with increased mortali- 
ty, relapse or GVHD [37]. A meta-analysis of 4 pros- 
pective studies evaluating the use of MRI to quantify 
pretransplant LIC failed to demonstrate a significant 
association between an elevated LIC (> 5 mg/gdw or > 
7 mg/gdw) and OS , while a serum ferritin >1000 ng/ml 
resulted to be a significant prognostic factor (HR 1.7, 
p=0.36). A significant association between an elevated 
LIC (> 7 mg/gdw) and NRM , was demonstrated only in 
a subgroup analysis of patients who received a 
reduced intensity HSCT (HR 2.2, p=0.26) [53].  
By contrast, Wermke et al. found that MRI-based 
LIC was an independent negative prognostic factor for 
NRM in 88 AML and MDS patients undergoing 
allogeneic HSCT: LIC  125 mol/g was a significant 
risk factor for NRM in uni-and multivariate analysis, and 
was associated with a decreased OS whereas serum 
ferritin and transfusion burden were not [38]. 
POSTTRANSPLANT COMPLICATIONS 
Mucositis 
Two studies addressed the issue of a potential 
impact of IO on the occurrence of severe mucositis. In 
a group of 50 patients receiving autologous HSCT, 
ferritin 1,500 μg/l was a predictor for severe mucositis 
either in univariate (50 vs 17%, P=0.05) and multivari- 
ate analysis (RR 2.3, P=0.028, CI 95% 1.3 to 79) [54]. 
In a retrospective analysis of 224 patients with 
haematological malignancies who underwent HSCT 
(n=142 autologous; 82 allogeneic HSCT), 143 patients 
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had serum ferritin levels <800 ng/mL (low serum ferritin 
group) and 81 patients had serum ferritin levels 800 
ng/mL (high serum ferritin group): patients with low pre-
transplant serum ferritin had significantly lower inciden- 
ce of grade 3 and 4 mucositis than patients with high 
pre-transplant serum ferritin either after autologous and 
allogeneic HSCT (p=0.05 and p=0.03 respectively [51]. 
Infections 
Several studies evaluated the relationship between 
infections and IO. Data from a retrospective review of 
bloodstream infections (BSI) in 114 consecutive pati- 
ents with AML and MDS who received an allogeneic 
HSCT between January 2000 and December 2008 
Table 1: Studies Evaluating the Impact of Pretransplantation Serum Ferritin Levels on Clinical Outcomes 
Prognostic Impact 
Ref. Study 
No. Patients - 
Diagnosis 
HSCT 
Cut-off for  
Pre-HSCT 
Serum  
Ferritin OS DFS NRM Other Variables 
Altes A 
BMT 2002 [4] 
prospective 
25 patients. Acute 
leukemia, CML, 
lymphoma 
Autologous (15) 
Allogeneic (10) 
 3000 ng/mL reduced - increased - 
Armand P 
Blood 2007[3] 
retrospective 
590 patients. 
Hematologic 
malignancies 
Allogeneic 
(myeloablative) 
 2515 ng/mL reduced 
Reduced 
(AML, 
ALL, 
MDS) 
Increased 
(MDS) 
Increased risk of VOD 
Altes A 
Ann Hematol  
2007[54] 
prospective 
81 patients. 
Hematologic 
malignancies 
Autologous (50) 
Allogeneic (31) 
 1500 ng/mL - - - 
Higher rate of severe 
mucositis, bacteremia, 
days with fever
2
 
Mahindra A 
BBMT 2008 [41] 
prospective 
315 patients.  
HD and NHL 
autologous  685 ng/mL reduced - No effect Higher rate of relapse 
Mahindra A 
BJH 2009 [42] 
retrospective 
222 patients.  
AML, ALL, CML, 
MDS, NHL 
Allogeneic 
(myeloablative) 
1910 ng/mL reduced - increased Reduced rate of 
cGVHD 
Mahindra A 
BMT 2009 [43] 
retrospective 
64 patients. 
Hematologic 
malignancies 
Allogeneic 
(nonablative) 
 1615 ng/mL reduced - - - 
Tachibana T 
Lek Lymph 2012 [47] 
prospective 
261 patients.  
AML, ALL, MDS 
allogeneic  1000 ng/mL reduced reduced increased - 
Pullarkat V 
BMT 2008 [9] 
prospective 
190 patients. 
Hematologic 
malignancies 
allogeneic  1000 ng/mL reduced - increased Increased risk of 
aGVHD and BSI 
Platzbecker U 
BBMT 2008 [50] 
retrospective 172 patients. MDS allogeneic  1000 ng/mL reduced1
 
 No effect 
Increased risk of 
aGVHD; higher HCT-CI 
Kataoka K 
BBMT 2009 [44] 
retrospective 
264 patients. 
Hematologic 
malignancies 
allogeneic  599 ng/mL reduced - increased - 
Kim YR 
A. Hemat 2009 [81] 
retrospective 
38 patients.Myeloid 
malignancies 
Allogeneic 
(RIST) 
>1578 ng/mL reduced reduced No effect - 
Alessandrino  
Haematol. 2010 [49] 
retrospective 357 patients. MDS Allogeneic  1000 ng/mL reduced - increased - 
Sucak GT 
Transpl Proc  
2010 [82] 
retrospective 
250 patients. 
Hematologic 
malignancies 
Allogeneic (148) 
Autologous (102) 
 500 ng/mL reduced - Increased3
 
Higher rate of fungal 
infections,SOS, severe 
mucositis
4
 pneumonia
4
 
Tachibana T 
BMT 2011 [83] 
prospective 
119 patients. AML, 
MDS 
allogeneic  1000 ng/mL reduced reduced No effect - 
Armand P 
Am J Hem. 2012 [37] 
prospective 
45 patients. ALL, 
AML, MDS 
Allogeneic 
(myeloablative) 
 1000 ng/mL reduced - No effect - 
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showed that BSI occurred in 36 of the 114 (32%) 
patients and the median time onset of the first BSI was 
day 28 (range day 0–95) after transplantation [8]. 
Interestingly, there was a significant difference in the 
incidence of BSI between the low ferritin group (<1000 
ng/mL: BSI incidence 21%) and the high ferritin group 
(1000 ng/mL; BSI incidence 42%) (P=0.02). 
Kanda et al. retrospectively analyzed the data of 
112 consecutive adult patients with hematological 
malignancies who received an allogeneic HSCT 
without antibacterial prophylaxis. Overall, the 
cumulative incidence of bacterial infection at 30 days 
after transplantation was 16%. High serum ferritin 
(>700 ng/mL) and high C-reactive protein (>0.3 mg/dL,) 
levels were significantly associated with the 
development of bacterial infection in a multivariate 
analysis. In addition, septic shock and sepsis with 
organ failure were exclusively observed in patients who 
had high ferritin and/or high CRP levels [21]. 
Pullarkat et al. showed in a group of 190 patients 
with haematological malignancies that there was a 
significant difference between the high- (1000 ng/mL) 
and low-ferritin groups (< 1000 ng/mL) for the 
incidence of BSI (44% vs 60%, P=0.042). In 
multivariate analysis, the odds for developing BSI were 
higher in the high-ferritin category (odds ratio=1.99, 
Wald test P=0.032) [9]. 
In a prospective study, a ferritin level >1,500 ng/mL 
was associated with the presence of BSI and the 
number of days with fever following autologous HSCT, 
in both univariate and multivariate analysis, while in 
allogeneic HSCT recipients this variable did not reach 
statistical significance [54]. Virtanen et al. evaluated 
whether pretransplant IO measured by MRI was 
predictive of severe infections in 67 allogeneic HSCT 
recipients: hepatic IO (defined as hepatic iron 
concentration> 36 μmol/g liver dry weight) was present 
in 78% of the patients while cardiac R2* was normal in 
all patients. Hepatic IO was significantly associated 
with severe infections in the early posttransplant period 
and significantly reduced the risk of acute and chronic 
GVHD [55]. 
A retrospective study analyzed the significance of 
serum hepcidin levels as a predictor of infectious 
complications after allogeneic HSCT [56]. The cumula- 
tive incidence of documented bacterial infections at day 
100 was evaluated according to pretransplant hepcidin 
levels: the incidence of bacterial infections, was 
significantly higher in the high-hepcidin group (50 
ng/mL) than in the low-hepcidin group (<50 ng/mL) 
(65% vs 11%; P<0.001). 
Several studies have evaluated the relationship 
between pretransplantation ferritin levels and the 
development of invasive fungal infections (IFI) [26, 57]  
Sivgin et al. evaluated the pretransplantation serum 
ferritin levels in 73 patients with pneumonia: the 
median ferritin levels were 1705 ng/ml (41–7198) in the 
group of patients with invasive fungal pneumonia and 
845 ng/ml (18–7099) in the non-fungal pneumonia 
group, respectively (p = 0.001). A threshold of 1550 
ng/ml for serum ferritin indicated an increased risk of 
fungal pneumonia [22]. 
Similarly, Ozyilmaz et al. found in multivariate 
analysis that increased ferritin levels (>1000ng/ml; 
OR: 3.42, 95% CI 1.03–11.42, P=0.045) and the 
development of sinusoidal obstruction syndrome (OR: 
5.09, 95% CI 1.53–16.90, P=0.008) were significant 
risk factors for fungal pneumonia [25]. 
According to these findings the presence of IO has 
been now considered as a risk factor for the 
development of IFI in patients undergoing allogeneic 
HSCT [58]. 
Graft-Versus-Host Disease 
GVHD is a major hindrance to the success of 
HSCT, contributing substantially to morbidity and 
transplant-associated mortality. . Acute GVHD usually 
develops at the time of engraftment and the incidence 
ranges between 20% and 70%, depending on the 
extent of histocompatibility mismatches, the age of the 
recipient and the intensity of preparative regimens. 
GVHD is caused by donor T lymphocytes reactive 
to histocompatibility antigens of the host. Significant 
experimental data suggest that dysregulated cytokine 
production occurs after allogeneic HSCT as a cascade 
of events involving sequential T cell and monocyte 
activation and is responsible for many of the 
manifestations of GVHD. During the first phase, the 
release of proinflammatory cytokines (IL-1, IL-8, TNF) 
may determine the initial histopathological damage in 
GVHD target organs. This initial cytokine release is 
further amplified in the second phase via the activation 
of donor T cells reacting to host tissue antigens, while 
the final phase involves further host tissue damage at 
the level of both effector cells and release of 
predominating Th1 type cytokines (IL-2, IFN- , TNF- ) 
[59]. Based on these observations, it is possible to 
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speculate that host tissue damage exacerbated by iron 
burden may have detrimental effects for the develop- 
ment of GVHD.  
The effect of elevated pretransplant ferritin levels 
(defined as ferritin 1000 ng /ml) on acute GVHD was 
assessed in 190 patients with hematological 
malignancies who received an allogeneic HSCT, 
showing that the high-ferritin levels increased the odds 
of GVHD and death by 3.11-fold - [9]. Another study 
showed that grade III-IV acute GVHD was significantly 
higher in patients with ferritin values > 2500 mg/L as 
compared to patients with lower ferritin levels (46 % vs 
18 %; p=.031) [50]. Conversely, Mahindra et al. found 
that patients with pretransplant ferritin levels > 1910 
ng/mL had a significantly lower incidence of limited and 
extensive chronic GVHD (26% vs 47%, p= 0.019) and 
a lower incidence of acute GVHD (48% vs 69%, 
p=0.10). [42] Similarly, high ferritin levels greater than 
400 ng/mL were associated with a 50% reduced risk of 
chronic GVHD [60], supporting the evidence for the 
suppressive effect of iron burden on adaptive immune 
responses [28, 61]. 
Overall, these conflicting results strengthen the 
need for further prospective studies to address the 
association of IO and the occurrence of GVHD. 
Hepatic Dysfunction and Veno-Occlusive Disease 
(VOD) 
Since liver represents one of the target organs 
where iron may accumulate preferentially, we can exp- 
ect that hepatic injuries following transplantation, might 
be more consistent in those patients with iron overload. 
Liver dysfunction is a very common complication of 
allogeneic HSCT, occurring in 57%-80% of patients: 
GVHD, drug toxicity, VOD, and infections are the most 
common factors potentially responsible of liver 
dysfunction in allogeneic HSCT recipients. [62]. VOD 
usually occurs in the first 3-4 weeks after HSCT as a 
result of endothelial and hepatocyte damage caused by 
the chemo-radiotherapy of the conditioning regimen, 
however more recently, this form of liver disease has 
been renamed as sinusoidal obstruction syndrome 
(SOS) because the sinusoidal cells are the primary 
target of the toxic injury. [63]. IO has been identified as 
a potential risk factor for the development of SOS [64- 
65]: Armand et al. found that pretransplantation ferritin 
in the top quartile ( 2515 ng/nL) was associated with a 
borderline significant increase in the risk of VOD (P=0 
.054) [3]. Busca et al. found that 54% of the patients 
with a post-HSCT ferritin level <1000 ng/mL had at 
least 1 abnormal liver function tests value, compared 
with 84% of the patients with post-HSCT 
hyperferritinemia (P=0.001), and multivariate analysis 
confirmed a significant correlation between 
hyperferritinemia and liver dysfunction. [35]. 
EVALUATION OF IRON OVERLOAD IN THE POST- 
TRANSPLANT PERIOD 
In general, data regarding hyperferritinemia and IO 
after HSCT are scarce.  
Majhail et al. evaluated the prevalence of IO in 56 
recipients of allogeneic HSCT who survived for a 
median of 28 months from transplant: serum ferritin 
>1000 mcg/ml was present in 19 patients and 18 of 
these had IO as determined by R2 MRI (defined as a 
LIC>1.8 mg/g), resulting in an overall prevalence of 
32%. [66]. 
Busca et al. have evaluated posttransplant IO by 
means of serum ferritin and SQUID in a cohort of 102 
adult patients who received an allogeneic HSCT. IO 
assessment was performed at a median time of 578 
days after HSCT, and 44% of the patients has serum 
ferritin level > 1000 ng/ml. A significant correlation was 
found between a ferritin level >1000 ng/mL and the 
presence of at least one abnormal liver function test, 
and the rate of proven/probable invasive fungal disease 
was significantly higher in patients with hyperferritine- 
mia (13% vs 0%; P5.006) [35]. 
 Meyer and colleagues analysed iron parameters in 
290 patients who received myeloablative HSCT, 
showing that ferritin levels peaked during the first 3 
months posttransplant and then tended to decrease to 
below pre-HSCT levels in long-term survivors: a serum 
ferritin level >1000 ng/ml was found in 62% of the 
patients before the transplant and in 64%, 51%, 38% 
and 12% of the patients at 6, 12, 24 and 60 months 
post-HSCT, respectively. More importantly, elevated 
pre-HSCT ferritin levels were associated with increased 
NRM and reduced OS, even in 6-, 12- and 24-month 
landmark analyses. The adverse effect of hyperferri- 
tinemia appeared to depend on both an increased risk 
of relapse and an increased risk of NRM. Taken as 
whole, the results of the study of Meyer et al suggest 
that interventions to reduce excessive body iron might 
be beneficial both before and after the transplant. [67]. 
Grobekatthofer et al. have investigated whether 
elevated post-HSCT serum ferritin might correlate to 
acute or chronic GVHD in 131 pediatric patients 
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receiving allogeneic HSCT. Although they reported a 
low incidence of acute GVHD grade II-IV (10%) and 
chronic GVHD (25%), the study showed that post-
HSCT hyperferritinemia was significantly associated 
with decreased survival and multi-organ failure, while 
did not demonstrate any impact on both acute and 
chronic GVHD. [68]. 
THERAPEUTIC MANAGEMENT OF IRON OVER- 
LOAD AFTER HSCT 
Given the potential detrimental effect of IO on the 
outcome of haematological patients undergoing 
allogeneic HSCT, there is a growing body of evidence 
supporting the removal of iron excess, although defined 
criteria for when and how to treat iron burden have not 
been established.  
Guidelines Recommendations 
The majority of the guidelines published so far have 
evaluated the management of IO in patients with MDS 
(69-72). All the Authors agree that MDS patients who 
are candidate to allogeneic HSCT with ferritin > 1000 
ng/ml or transfusion requirement of 2 units per months 
for over 1 year should receive iron chelation before the 
transplant. 
Indeed, two guidelines only have been developed to 
optimize the management of IO in patients receiving 
allogeneic HSCT. 
A consensus promoted by GITMO provided 
recommendations to support the appropriate choice for 
IO assessment and treatment in patients with MDS 
receiving an allogeneic HSCT [73]. The guidelines 
recommend that, MDS patients candidate to allogeneic 
HSCT should be evaluated for IO considering transfu- 
sion history, previous iron chelation, serum iron level, 
total iron binding capacity, serum ferritin, and percen- 
tage of transferring saturation. In patients with clinical 
signs of liver and/or heart damage, MRI T2 for cardiac 
study and MRI R2 for liver iron study should be perfor- 
med. Liver biopsy is not routinely recommended in 
these patients. The Expert Panel agrees that all MDS 
patients who are transfusion dependent and are poten- 
tial candidate to allogeneic HSCT should receive iron 
chelation treatment to prevent IO. Nevertheless, it is 
worthwhile recalling that the achievement of a reduc- 
tion in IO should not cause a delay in transplantation. 
The EBMT Joint recommendations about screening 
and preventive practices for long term survivors after 
hematopoietic cell transplantation [74] recommend that 
liver function tests must be evaluated every 3-6 months 
for the first year after the transplant, and then at least 
yearly. Serum ferritin should be measured one year 
post transplant, however since ferritin value may be 
confounding as ferritin is an acute phase reactant, 
when its value is abnormal, confirmatory liver biopsy or 
magnetic resonance imaging should be considered 
based upon the clinical conditions of the patient and 
the magnitude of ferritin increase. Subsequent monitor- 
ing is suggested for patients with continued RBC 
transfusions or hepatitis C infection. Transplant surviv- 
ors with persistent IO must be considered for ferroche- 
lation once engraftment is stable and immun-osuppres- 
sive treatment discontinued. Therapeutic phlebotomy 
(450-500 ml every 6 to 8 weeks ) is advised as the 
treatment of choice in patients with more than 7 mg/kg 
dry weight liver iron; target iron status is serum ferritin 
within the normal laboratory range and transferrin 
saturation < 45%.  
Therapeutic options for IO include phlebotomy and 
iron chelation therapy with chelator agents. 
Phlebotomies 
Phlebotomy may be considered as the treatment of 
choice for IO in patients with full recovery of 
erythropoiesis after HSCT. Based on the experience in 
patients with thalassemia, phlebotomy is a relatively 
inexpensive procedure that has been shown to 
effectively reduce iron burden alone or in combination 
with erythropoietin (EPO) support [73]. 
Indeed, data regarding the use of phlebotomies in 
HSCT recipients are scarce. 
Busca et al. have evaluated the feasibility of 
phlebotomies in a small group of hematologic patients 
who received an allogeneic HSCT (35). Of 29 patients 
with evidence of IO based on LIC> 1000 mcg Fe/g wet 
weight, 19 (65%) were eligible for a phlebotomy 
program: 13 (68%) patients were able to complete the 
procedures reaching the target goal of ferritin level < 
500 ng/mL. Recombinant EPO was used in 2 cases to 
facilitate planned phlebotomy. The median LIC was 
1419 mg Fe/g ww (range, 1030-2384 mg Fe/g ww) 
before phlebotomy and 625 mg Fe/g ww (range, 250-
1703 mg Fe/g ww) after completion of the program 
(P<0.001). 
Venesections were performed in a group of 29 
patients with post-HSCT IO, resulting in ferritin normali- 
zetion in 24 out of 28 (86%) evaluable patients [39]. 
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Kamble et al. described the outcome of 6 patients 
with IO exacerbating hepatic GVHD, who were treated 
with phlebotomy. EPO assisted phlebotomy led to 
normalization of liver function tests and of serum ferritin 
after a median of 11 months [75]. 
Majhail et al. reported the first study prospectively 
evaluating the management of IO in a small cohort of 
16 allogeneic HSCT recipients with the use of 
phlebotomies or deferasirox (DFX): 8 patients under- 
went phlebotomies, 3 received DFX at the dose of 20 
mg/Kg/day for 6 months and 5 patients chose observa- 
tion only. Both treatments were reported to be well tole- 
rated leading to decrease of serum ferritin level [76]. 
Iron-Chelating Therapy 
Deferasirox (DFX) 
A large retrospective study evaluated the efficacy of 
DFX in 80 patients with IO (defined as serum ferritin > 
1000 ng/ml) before allogeneic HSCT [77]. Thirty-seven 
patients did not receive any treatment due to poor 
compliance, 43 patients received DFX treatment during 
the post-transplant period at the dose of 20-30 
mg/Kg/day; the median day of treatment start was 
day+85 post-transplant and the median duration of 
DFX treatment was 122 days. The iron chelating 
treatment significantly reduced serum ferritin levels 
(2684 ng/ml, median value pre-treatment; 1097 ng/ml, 
median value post-treatment, p<0.001). More patients 
died in the non-treatment group (76%) as compared to 
patients in the treatment group (33%), leading to a 
significant better OS and DFS , although it should be 
underscored that more patients in the non-treatment 
group died of relapsed disease (13%) as compared to 
patients who were treated with DFX (5%). In this 
respect, we cannot exclude a selection bias of patients 
unable to receive DFX due to poor compliance that 
might simply reflect the high risk features of this group 
of patients. 
Deferioxamine (DFO) and Deferiprone 
Few studies have investigated the use of DFO for 
the treatment of IO in allogeneic HSCT recipients. Lee 
et al. reported the outcome of 43 patients who received 
iron-chelating agents before HSCT, and 37 of these 
were treated with DFO [78]. They found a correlation 
between the number of infusions and the reduction of 
ferritin levels [78]. The group of Pesaro described 15 
thalassemic patients who received DFO before and 
after HSCT according to two schedules (from day -9 to 
day +60; from day -9 to day -2, and from day +28 to 
day +60) at the dose of 40 mg/Kg/day as a 24-hour i.v. 
infusion [79]. The treatment did not influence the 
engraftment or the incidence of GVHD but led to a 
consistent reduction of ferritin levels [79]. 
The requirement of a subcutaneous or continuous 
intravenous administration of the drug may be conside- 
red a deterrent for a wider use of DFO in patients 
undergoing HSCT. A further obstacle to the use of DFO 
is the potential association between the occurrence of 
mucomycosis and the administration of DFO. In parti- 
cular, mucorales have an absolute requirement for iron 
for their growth and survival, and DFO may function as 
a siderophore providing iron to the fungi [80].  
To our knowledge there are no data regarding the 
use of deferiprone in allogeneic HSCT recipients; the 
occurrence of neutropenia potentially associated with 
the use of deferiprone represents a major hindrance to 
the administration of this agent in the allogeneic HSCT 
setting. 
CONCLUSIONS 
The great interest for IO in allogeneic HSCT 
recipients is witnessed by the large number of studies 
published during the most recent years. Nevertheless, 
many unresolved issues still remain. 
The best tool to assess IO has not been identified: 
serum ferritin may be considered as the easiest way to 
estimate IO and the method most widely used 
worldwide. However, ferritin is a surrogate for IO and 
lacks of accuracy, while alternative methods, including 
SQUID and MRI, are expensive and, more importantly, 
are available in few Centers only. In addition, the best 
timing of assessment of IO has not defined precisely 
and usually relies on the policy in use at each 
transplant Center. Recent studies have questioned the 
association between IO and a poor patient outcome 
after HSCT. Since serum ferritin is an acute phase 
reactant, an elevation may simply mirror inflammatory 
conditions including an advanced disease phase that is 
well recognized to influence the outcome of 
hematologic patients receiving an allogeneic HSCT. On 
the other hand, several studies that quantified pre-
HSCT IO with MRI-based hepatic iron concentration 
measurement did not show unequivocally an 
association between IO and overall survival or 
transplant-related mortality. 
Phlebotomies may be considered as the standard of 
care for the treatment of IO, however only a minority of 
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HSCT recipients may benefit from this procedure due 
to the presence of concomitant anemia. Iron chelating 
agents, such as DFX, seem to have good safety 
profiles, however further investigations are required to 
confirm their efficacy in this setting. 
Hopefully, future large prospective clinical trials will 
address these issues. 
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